Equities

Arecor Therapeutics PLC

Arecor Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)140.00
  • Today's Change2.50 / 1.82%
  • Shares traded23.98k
  • 1 Year change-46.15%
  • Beta--
Data delayed at least 20 minutes, as of Mar 28 2024 16:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

  • Revenue in GBP (TTM)3.38m
  • Net income in GBP-9.42m
  • Incorporated2021
  • Employees51.00
  • Location
    Arecor Therapeutics PLCChesterford Research ParkLittle ChesterfordSAFFRON WALDEN CB10 1XLUnited KingdomGBR
  • Phone+44 122 342 6060
  • Websitehttps://arecor.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Verici DX PLC15.03k-8.87m22.44m14.00--2.98--1,492.30-0.0521-0.05210.000090.03110.0013--0.11521,002.26-77.76---92.28--84.21---59,015.79------0.0232-------36.94------
Skinbiotherapeutics PLC161.65k-2.88m23.38m11.00--6.32--144.61-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Hemogenyx Pharmaceuticals PLC0.00-7.17m23.65m14.00--5.49-----0.007-0.0070.000.00320.00----0.00-95.17-73.59-107.02-86.78-----------71.620.4735------21.96--46.18--
C4X Discovery Holdings PLC1.71m-11.11m25.22m49.00--3.86--14.75-0.0442-0.04420.00680.02590.1464--0.939334,897.96-95.10-66.17-117.91-76.7997.7897.43-649.77-416.04---6,707.000.061---36.64-24.70-36.16---16.37--
Destiny Pharma PLC0.00-5.97m26.21m20.00--2.20-----0.0759-0.07590.000.12510.00----0.00-48.68-47.98-52.87-52.05------------0.00-------21.80---45.97--
Science in Sport PLC65.93m-7.07m28.71m158.00--0.7213--0.4354-0.0464-0.04640.42390.21840.84794.203.83417,278.50-9.09-9.69-13.75-11.9741.8847.09-10.72-11.940.6921-2.310.2825--1.9732.50-96.47--49.81--
CRUSHMETRIC Group Ltd394.17k-870.26k29.96m20.00--1.19--76.01-0.0071-0.00710.00270.10510.02557.142.6419,708.43-5.72-40.65-8.35--34.6637.39-224.56-140.540.072-14.420.0558--119.19-1.40-7.26--12.11--
Arecor Therapeutics PLC3.38m-9.42m42.11m51.00--3.19--12.46-0.3108-0.31080.11140.43140.1805--0.751666,254.90-50.32---66.40-------278.81--2.28--0.0125--107.51---50.11------
Venture Life Group PLC48.57m-756.00k46.49m153.00--0.62897.740.9571-0.0066-0.00660.36350.58440.43632.473.78317,477.10-0.6791.75-0.75722.0138.5640.30-1.564.411.551.370.23750.0034.2422.33-78.35--37.59--
Poolbeg Pharma PLC0.00-4.89m48.25m12.00--2.91-----0.0098-0.00980.000.03310.00----0.00-25.02---25.91--------------0.00-------100.60------
Celadon Pharmaceuticals PLC20.74k-8.06m52.97m----16.90--2,554.12-0.1306-0.13060.00030.04880.0016267.850.0248---64.68---71.16---29,080.42---40,384.18--1.84-12.450.6052--------------
Eco Animal Health Group Plc88.46m-1.62m56.91m228.00--0.697823.610.6433-0.024-0.0241.311.200.76641.923.41387,986.80-0.19496.03-0.26458.0243.0546.41-0.25447.892.261.220.043755.723.794.89246.94-35.90-4.43--
Data as of Mar 28 2024. Currency figures normalised to Arecor Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

20.50%Per cent of shares held by top holders
HolderShares% Held
Lombard Odier Asset Management (Europe) Ltd.as of 04 Aug 20221.62m5.30%
Chelverton Asset Management Ltd.as of 30 Jun 20231.43m4.65%
Unicorn Asset Management Ltd.as of 04 Aug 20221.20m3.91%
Amati Global Investors Ltd.as of 04 Aug 2022844.04k2.76%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2023631.69k2.06%
CRUX Asset Management Ltd.as of 30 Sep 2023554.90k1.81%
More ▼
Data from 30 Sep 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.